Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the phase III COMMANDS trial of luspatercept during the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO).
The trial, which evaluated luspatercept versus epoetin alfa for treatment of anemia in patients with erythropoiesis-stimulating agent (ESA)-naive lower-risk myelodysplastic syndromes (LR-MDS) requiring red blood cell transfusions, showed that nearly twice as many patients achieved transfusion independence and hemoglobin increase with luspatercept.
The recent US Food and Drug Administration approval of luspatercept for the treatment of anemia without previous ESA use in adults with very low- to intermediate-risk MDS who may require regular red blood cell transfusions was based on interim results from the pivotal phase III COMMANDS trial.
Dr. Garcia-Manero presented data from the trial during the Eleventh Annual Meeting of SOHO. He previously presented results at the American Society of Clinical Oncology Annual Meeting in June 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.